Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331184

Institution ID

3331184

Institution full name and acronym

Società Italiana di Medicina Generale e delle Cure Primarie (SIMG)

Type of institution

Patient organisation/association

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

Arrhythmogenic Potential of Drugs (ARITMO) project
CharacTeristics of treAtment response to hIgh dose ICS/LABA vs. Medium or high dOse ICS/LABA + LAMA in patients with uncontRolled moderate to severe asthma on medium dose ICS/LABA - TAILOR study
European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-ADR Alliance
Multinational, multi-database cohort study to assess adverse cardiovascular and cerebrovascular outcomes and mortality in association with inhaled NVA237 in Europe (NVA237 PASS)
Multinational, multi-database drug utilization study of inhaled NVA237 in Europe (NVA237 DUS)
Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®)
Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure
Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies (SAFEGUARD)